Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc., a biopharmaceutical firm focusing on cancer, bacterial, and viral treatments, reported a decrease in total revenue by 6% in their 2023 financial results, with a notable 104% revenue increase in the United States. The company also saw a reduction in its net loss by 13% compared to the previous year, amidst varied changes in operating expenses, including a significant decrease in research and development costs for both device and drug divisions.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
